Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EXAS NASDAQ:GHDX NASDAQ:HALO NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXASExact Sciences$53.81+4.7%$48.73$38.81▼$72.83$10.19B1.053.24 million shs4.19 million shsGHDXGenomic Health$63.44$64.79$50.77▼$90.18$2.38B0.91.05 million shsN/AHALOHalozyme Therapeutics$74.93+2.1%$62.80$42.01▼$75.46$8.76B1.192.01 million shs1.89 million shsRGENRepligen$124.56+3.3%$121.53$102.96▼$182.52$7.01B1.07653,843 shs1.04 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXASExact Sciences+4.67%+13.48%+14.71%-1.93%-5.81%GHDXGenomic Health0.00%0.00%0.00%0.00%0.00%HALOHalozyme Therapeutics+2.08%+2.43%+20.22%+38.12%+20.60%RGENRepligen+3.30%+1.83%+11.12%-2.92%-13.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXASExact Sciences$53.81+4.7%$48.73$38.81▼$72.83$10.19B1.053.24 million shs4.19 million shsGHDXGenomic Health$63.44$64.79$50.77▼$90.18$2.38B0.91.05 million shsN/AHALOHalozyme Therapeutics$74.93+2.1%$62.80$42.01▼$75.46$8.76B1.192.01 million shs1.89 million shsRGENRepligen$124.56+3.3%$121.53$102.96▼$182.52$7.01B1.07653,843 shs1.04 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXASExact Sciences+4.67%+13.48%+14.71%-1.93%-5.81%GHDXGenomic Health0.00%0.00%0.00%0.00%0.00%HALOHalozyme Therapeutics+2.08%+2.43%+20.22%+38.12%+20.60%RGENRepligen+3.30%+1.83%+11.12%-2.92%-13.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXASExact Sciences 2.88Moderate Buy$67.0524.61% UpsideGHDXGenomic Health 0.00N/AN/AN/AHALOHalozyme Therapeutics 2.33Hold$67.11-10.43% DownsideRGENRepligen 2.73Moderate Buy$169.5536.12% UpsideCurrent Analyst Ratings BreakdownLatest GHDX, EXAS, HALO, and RGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025EXASExact SciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/3/2025RGENRepligenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$180.009/2/2025RGENRepligenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$205.009/2/2025HALOHalozyme TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/18/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$75.00 ➝ $80.008/12/2025EXASExact SciencesBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $60.008/11/2025EXASExact SciencesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$70.00 ➝ $60.008/8/2025EXASExact SciencesEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$68.00 ➝ $64.008/7/2025EXASExact SciencesCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/7/2025EXASExact SciencesUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$61.00 ➝ $53.008/7/2025EXASExact SciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$54.00 ➝ $46.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXASExact Sciences$2.76B3.69$5.63 per share9.56$12.98 per share4.15GHDXGenomic Health$394.11M6.05$1.45 per share43.76$7.48 per share8.48HALOHalozyme Therapeutics$1.02B8.63$4.65 per share16.11$2.86 per share26.20RGENRepligen$634.44M11.05$3.11 per share40.09$35.21 per share3.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXASExact Sciences-$1.03B-$5.43N/A107.625.50-34.19%-1.75%-0.76%11/4/2025 (Estimated)GHDXGenomic Health$25.68M$1.0560.4236.88N/A12.81%19.62%14.89%N/AHALOHalozyme Therapeutics$444.09M$4.3717.1512.050.4147.28%150.85%29.19%10/30/2025 (Estimated)RGENRepligen-$25.51M-$0.25N/A52.782.29-2.05%4.61%3.24%11/11/2025 (Estimated)Latest GHDX, EXAS, HALO, and RGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025EXASExact Sciences-$0.02$0.22+$0.24-$0.01$774.43 million$811.09 million8/5/2025Q2 2025HALOHalozyme Therapeutics$1.23$1.54+$0.31$1.33$282.66 million$325.72 million7/29/2025Q2 2025RGENRepligen$0.40$0.37-$0.03$0.26$174.62 million$182.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXASExact SciencesN/AN/AN/AN/AN/AGHDXGenomic HealthN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXASExact Sciences0.942.892.56GHDXGenomic Health0.155.965.96HALOHalozyme Therapeutics4.548.367.01RGENRepligen0.268.597.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXASExact Sciences88.82%GHDXGenomic Health93.87%HALOHalozyme Therapeutics97.79%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipEXASExact Sciences1.20%GHDXGenomic Health31.30%HALOHalozyme Therapeutics2.40%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXASExact Sciences7,000189.32 million187.05 millionOptionableGHDXGenomic Health82937.59 millionN/AOptionableHALOHalozyme Therapeutics390116.97 million114.16 millionOptionableRGENRepligen1,77856.26 million55.58 millionOptionableGHDX, EXAS, HALO, and RGEN HeadlinesRecent News About These CompaniesAlyeska Investment Group L.P. Boosts Holdings in Repligen Corporation $RGENSeptember 6 at 6:45 AM | marketbeat.comRepligen (NASDAQ:RGEN) Given "Buy" Rating at HC WainwrightSeptember 6 at 2:59 AM | americanbankingnews.comRepligen (NASDAQ:RGEN) Earns "Buy" Rating from HC WainwrightSeptember 5 at 8:25 AM | marketbeat.comAWM Investment Company Inc. Cuts Stock Holdings in Repligen Corporation $RGENSeptember 5 at 7:11 AM | marketbeat.comRepligen Corporation $RGEN Stock Holdings Lowered by 12 West Capital Management LPSeptember 5 at 6:08 AM | marketbeat.comRepligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 4 at 11:12 AM | seekingalpha.comFirst Light Asset Management LLC Has $11.18 Million Stock Holdings in Repligen Corporation $RGENSeptember 4 at 7:27 AM | marketbeat.comJump Financial LLC Takes $343,000 Position in Repligen Corporation $RGENSeptember 4 at 3:56 AM | marketbeat.comBaird Financial Group Inc. Sells 53,084 Shares of Repligen Corporation $RGENSeptember 3 at 5:53 AM | marketbeat.comHsbc Holdings PLC Invests $478,000 in Repligen Corporation $RGENSeptember 3 at 3:57 AM | marketbeat.comRepligen price target raised to $205 from $204 at RBC CapitalSeptember 3 at 3:23 AM | msn.comRepligen Appoints Violetta Hughes as Chief Accounting OfficerSeptember 2, 2025 | tipranks.comRepligen Corporation $RGEN Shares Sold by Parnassus Investments LLCAugust 31, 2025 | marketbeat.comRepligen Corporation $RGEN Shares Sold by Champlain Investment Partners LLCAugust 29, 2025 | marketbeat.comRepligen Corporation $RGEN Shares Acquired by Comerica BankAugust 29, 2025 | marketbeat.comRepligen Corporation $RGEN Shares Acquired by Synovus Financial CorpAugust 29, 2025 | marketbeat.comAmeriprise Financial Inc. Has $87.16 Million Stock Holdings in Repligen Corporation $RGENAugust 28, 2025 | marketbeat.comNorthern Trust Corp Raises Position in Repligen Corporation $RGENAugust 28, 2025 | marketbeat.comRepligen Corporation $RGEN Shares Bought by CW Advisors LLCAugust 27, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Buys 101,791 Shares of Repligen Corporation $RGENAugust 26, 2025 | marketbeat.comRepligen Corporation (NASDAQ:RGEN) Receives Average Rating of "Moderate Buy" from BrokeragesAugust 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025CrowdStrike at a Crossroads: AI Halo vs. RisksBy Chris Markoch | August 28, 2025GHDX, EXAS, HALO, and RGEN Company DescriptionsExact Sciences NASDAQ:EXAS$53.81 +2.40 (+4.67%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$53.50 -0.31 (-0.58%) As of 09/5/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Genomic Health NASDAQ:GHDXGenomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.Halozyme Therapeutics NASDAQ:HALO$74.93 +1.53 (+2.08%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$74.14 -0.79 (-1.05%) As of 09/5/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Repligen NASDAQ:RGEN$124.56 +3.98 (+3.30%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$124.58 +0.02 (+0.02%) As of 09/5/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
